Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837330 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
A Phase 1 study, sponsored by Southeast Retina Center, Georgia.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00837330: Completed Phase 1 study, sponsored by Southeast Retina Center, Georgia.
NCT00837330 is a Phase 1 study that has completed, run by Southeast Retina Center, Georgia. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00837330, a Phase 1 study, has completed, sponsored by Southeast Retina Center, Georgia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. These abnormal blood vessels can bleed or leak fluid, causing disruption of normal retinal function and vision loss. Ranibizumab is a drug that is FDA-approved for the treatment of wet age-related macular degeneration (AMD) and is injected directly into the eye. Given the efficacy of ranibizumab in the treatment of wet AMD, and the postulated similarity between the disease mechanisms involved in both wet AMD and PCV, we believe ranibizumab will have a beneficial effect on visual function in patients with PCV.
Primary Outcome
Incidence and severity of ocular adverse events, as identified by indirect and direct examination. Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more of clinical macula (arcade to arcade), disease-related vitreous hemorrhage, injection-related endopthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital s
Interventions
- DRUG ranibizumab 0.5 or 0.3 mg/0.05 cc
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
What the finished NCT00837330 record still lists
NCT00837330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which ranibizumab 0.5 or 0.3 mg/0.05 cc is the first listed.
NCT00837330 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00837330 about?
NCT00837330 is a clinical study titled "Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy". This Phase I/II safety study is designed to investigate the safety and efficacy of ranibizumab (Lucentis) in the treatment of polypoidal choroidal vasculopathy (PCV), a potentially blinding eye disease that involves the growth of tiny, abnormal blood vessels under the retina. These abnormal blood ve...
What is the current status of trial NCT00837330?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2006-05. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00837330?
The interventions under investigation include: ranibizumab 0.5 or 0.3 mg/0.05 cc (DRUG).
Who is sponsoring clinical trial NCT00837330?
This trial is sponsored by Southeast Retina Center, Georgia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00837330's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia